Phase I Clinical Trial to Assess the Safety and Pharmacokinetic Profile of CKD-581 in Patients With Lymphoma or Multiple Myeloma Failed to Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs CKD 581 (Primary)
- Indications Lymphoma; Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Chong Kun Dang
- 09 Mar 2018 Results published in the Investigational New Drugs
- 03 Oct 2016 Status changed from recruiting to completed.
- 31 Jul 2015 Planned End Date changed from 1 May 2013 to 1 Oct 2016 as per ClinicalTrials.gov record.